6 citations
,
March 2021 in “International Journal of Pharmaceutics” This study reported that a subcutaneous injection formulation using PLGA microspheres to release finasteride stably achieved sustained monthly drug delivery without burst release in beagle dogs, with a dose of 16.8 mg identified as optimal for potential first-in-human trials.
December 2022 in “International Journal of Pharmaceutics” This study estimated the starting dose range for a finasteride long-acting injectable formulation in humans, suggesting that 16.80 mg may be the optimal starting dose.
17 citations
,
August 2024 in “International Journal of Biological Macromolecules” The hydrogel dressings speed up healing and reduce scarring.
April 2026 in “Frontiers in Pharmacology” This study suggests that nanotechnology-based drug delivery systems can improve the targeted, sustained delivery and stability of dermatological treatments, potentially leading to better outcomes and reduced side effects for various aesthetic skin conditions, though further clinical trials are needed to confirm these benefits.
January 2026 in “Dermatologic Surgery” In this systematic review, researchers found that injectable therapies, including agents like dutasteride and multivitamin formulations, may offer cosmetic benefits for androgenetic alopecia; however, evidence is limited by small study sizes, varied methods, and short follow-up periods, necessitating standardized trials for routine use recommendations.